| Literature DB >> 24010526 |
Edith Patouillard1, Immo Kleinschmidt, Kara Hanson, Sochea Pok, Benjamin Palafox, Sarah Tougher, Kate O'Connell, Catherine Goodman.
Abstract
BACKGROUND: There is increased interest in using commercial providers for improving access to quality malaria treatment. Understanding their current role is an essential first step, notably in terms of the volume of diagnostics and anti-malarials they sell. Sales volume data can be used to measure the importance of different provider and product types, frequency of parasitological diagnosis and impact of interventions. Several methods for measuring sales volumes are available, yet all have methodological challenges and evidence is lacking on the comparability of different methods.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24010526 PMCID: PMC3848597 DOI: 10.1186/1475-2875-12-311
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Data collected on wholesale and retail sales volumes using recall and retail audit methods
| | ||||
|---|---|---|---|---|
| | ||||
| Total products surveyed | 104 (100%) | 34 (100%) | 143 (100%) | 42 (100%) |
| Recall method (RC) | | | ||
| Sales volume data collected | 76 (73.1%) | 26 (76.5%) | 130 (91.0%) | 41 (97.6%) |
| - Not remembered | 17 (16.3%) | 7 (21.6%) | 3 (2.8%) | 1 (2.4%) |
| - Refused | 11 (10.6%) | 1 (2.9%) | - | - |
| - Missing2 | - | - | 10 (7.0%) | - |
| Retail Audit method (RA) | | | ||
| Sales volumes data calculated (excluding negatives) | 82 (78.8%) | 29 (85.3%) | 115 (80.4%) | 35 (83.3%) |
| Sales volumes data calculated (including negatives)3 | 94 (90.4%) | 31 (91.2%) | 121 (84.6%) | 39 (92.9%) |
| Stock data collected | 96 (92.3%) | 31 (91.2%) | 121 (84.6%) | 39 (92.9%) |
| - Refused | 8 (7.7%) | 3 (8.8%) | 12 (8.4%) | 3 (7.1%) |
| - Missing2 | - | - | 10 (7.0%) | - |
| Received quantities collected | 103 (99.0%) | 33 (97.1%) | 133 (93.0%) | 42 (100.0%) |
| - Refused | 1 (1.0%) | 1 (2.9%) | - | - |
| - Missing2 | - | - | 10 (7.0%) | |
| Disposed quantities collected | 101 (97.1%) | 33 (97.1%) | 133 (93.0%) | 42 (100.0%) |
| - Refused | 3 (2.9%) | 1 (2.9%) | - | - |
| - Missing2 | - | - | 10 (7.0%) | |
1At the second visit of RA during which RC was implemented. 2missing strength data impeded calculation of data in terms of adult equivalent treatment doses. 3negative sales volume estimates were obtained when calculating (quantities in stock at 1st visit + quantities received in-between the 2 visits – quantities at 2nd visit – quantities disposed in-between the 2 visits), e.g. quantities stocked at second visit were higher than quantities stocked at first visit although shopkeepers did not report any quantities received. These negative estimates were excluded from the analysis.
Figure 1Scatter plots of the between-method differences (RA-RC) against mean volumes of sales measured. A. Between-method differences (RA-RC) against volumes measured for anti-malarial sold at wholesale outlets. B. Between-method differences (RA-RC) against volumes measured for anti-malarials sold at retail outlets. C. Between-method differences (RA-RC) against volumes measured for RDTs sold at wholesale outlets. D. Between-method differences (RA-RC) against volumes measured for RDTs sold at retail outlets. RC: recall, RA: retail audit, RDTs: rapid diagnostic tests, AETD: Adult Equivalent Treatment Dose.